February 2026
1. PALANDRI F, Caocci G, Abruzzese E, Tiribelli M, et al
   Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.
   Cancer. 2026;132:e70320.
   

   >> Share

   
   
2. BUCHRITS S, Rozental A, Korngold N, Algor O, et al
   Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
   Cancer. 2026;132:e70265.
   

   >> Share

   
   December 2023
3. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
   Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
   Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
   

   >> Share

   
   June 2023
4. PALANDRI F, Breccia M, Mazzoni C, Auteri G, et al
   Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
   Cancer. 2023;129:1704-1713.
   

   >> Share

   
   March 2023
5. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
   Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies".
   Cancer. 2023 Mar 14. doi: 10.1002/cncr.34736.
   

   >> Share

   
   
6. MANCUSO A, Butera G, Rossi M, Maringhini A, et al
   Hepatocellular carcinoma in thalassemia and other hemoglobinopathies.
   Cancer. 2023 Mar 14. doi: 10.1002/cncr.34735.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share